osimertinib,tepotinib
astrazeneca,merck
['insight2', 'tepotinib']
 presenting impt data from insight2 looking at osi + tepotinib for met based resistance. excellent responses and limited tox with combination. justifies looking for met #esmo22 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v